Apple Tree Partners (ATP), a NYC-based life sciences fund, appointed Michael Ehlers, M.D., Ph.D., as Chief Scientific Officer and Venture Partner, and as Chief Executive Officer of portfolio company Limelight Bio effective October 21, 2019.
Ehlers will bring focus on science and innovation, entrepreneurship, patient-centric clinical design and big-picture thinking to ATP.
Dr. Ehlers will serve as Chief Executive Officer of ATP portfolio company Limelight Bio, a biotech company developing novel gene therapies. Using a suite of proprietary technologies, Limelight is developing treatments for debilitating inherited diseases of the eye, brain, muscle, and liver, including treatments for diseases that cannot be addressed by current gene therapy methods.
Most recently, Dr. Ehlers was Executive Vice President and Head of Research & Development at Biogen, where he served on the executive committee and was responsible for setting a vision and overseeing more than $2 billion annually in R&D investment.
During his time at Biogen, Dr. Ehlers expanded and diversified Biogen’s clinical portfolio and boosted R&D productivity across the value chain.
Previously, Dr. Ehlers was Senior Vice President & Head, BioTherapeutics R&D and the Chief Scientific Officer for Neuroscience & Pain at Pfizer.
Prior to joining industry in 2010, he was the George Barth Geller Professor of Neurobiology and an Investigator of the Howard Hughes Medical Institute at Duke University Medical Center.
Dr. Ehlers earned his bachelor’s degree in chemistry from the California Institute of Technology and holds M.D. and Ph.D. degrees from the Johns Hopkins University School of Medicine.
Led by Managing Partner Seth Harrison, M.D.. ATP is a life sciences fund with global presence and reach that is developing the next generation of transformative biotechnology companies. The firm works with innovative life scientists and provides the capital, expertise, and operational intelligence to build new companies and drive long-term value.